Jump to content

Fasoracetam

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Buddhafinder (talk | contribs) at 04:41, 3 June 2017 (Undid revision 783330448 by Jytdog (talk) FDA approved human phase 2/3 trials are significant, deserve to be noted.). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Fasoracetam
Names
IUPAC name
(5R)-5-(piperidine-1-carbonyl) pyrrolidin-2-one
Other names
(5R)-5-oxo-D-prolinepiperidinamide
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
KEGG
  • InChI=1S/C10H16N2O2/c13-9-5-4-8(11-9)10(14)12-6-2-1-3-7-12/h8H,1-7H2,(H,11,13)/t8-/m1/s1 checkY
    Key: GOWRRBABHQUJMX-MRVPVSSYSA-N checkY
  • InChI=1/C10H16N2O2/c13-9-5-4-8(11-9)10(14)12-6-2-1-3-7-12/h8H,1-7H2,(H,11,13)/t8-/m1/s1
    Key: GOWRRBABHQUJMX-MRVPVSSYBL
  • O=C(N1CCCCC1)[C@@H]2NC(=O)CC2
Properties
C10H16N2O2
Molar mass 196.250 g·mol−1
Pharmacology
Oral
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
☒N verify (what is checkY☒N ?)

Fasoracetam (NS-105, 5-oxo-D-prolinepiperidinamide monohydrate)[1] is a research chemical of the racetam family.[2] It is a nootropic, and has been in a clinical trial for attention deficit hyperactivity disorder.[3]

In in vitro studies on mouse neurons, fasoracetam modulated mGluR II/III activity.[4] In studies in rats, it blocked memory disruptions caused by baclofen, a GABAB agonist[5] and upregulated production of GABAB receptors after repeat dosing.[6]

Experimental Medical Uses

In a five-week, single-site, phase one trial, 30 adolescents with ADHD and genetic disorders impacting metabotropic glutamate receptors (mGluRs) showed improvement in symptoms. [7][8] Medgenics, an emerging pharmaceutical firm, has acquired the rights to develop this medication as of September, 2015. They describe fasoracetam as "a first-in-class non-stimulant, metabotropic glutamate receptor modulator." [9] Medgenics announced a phase 2/3 clinical trial in June, 2016. [10]

References

  1. ^ FDA/NIH Substance registration system. Page accessed March 21, 2016
  2. ^ "5-oxo-D-prolinepiperidinamide monohydrate - Compound Summary". Retrieved 21 July 2013.
  3. ^ "Drug Profile Fasoracetam".
  4. ^ Oka, M; Itoh, Y; Tatsumi, S; Ma, FH; Ukai, Y; Yoshikuni, Y; Kimura, K. "A novel cognition enhancer NS-105 modulates adenylate cyclase activity through metabotropic glutamate receptors in primary neuronal culture". Naunyn Schmiedebergs Arch Pharmacol. 356: 189–96. doi:10.1007/pl00005040. PMID 9272724..
  5. ^ Ogasawara, T; Itoh, Y; Tamura, M; Mushiroi, T; Ukai, Y; Kise, M; Kimura, K. "Involvement of cholinergic and GABAergic systems in the reversal of memory disruption by NS-105, a cognition enhancer". Pharmacol Biochem Behav. 64: 41–52. doi:10.1016/s0091-3057(99)00108-2. PMID 10494996.
  6. ^ Shimidzu, T; Itoh, Y; Oka, M; Ishima, T; Ukai, Y; Yoshikuni, Y; Kimura, K. "Effect of a novel cognition enhancer NS-105 on learned helplessness in rats: possible involvement of GABA(B) receptor up-regulation after repeated treatment". Eur J Pharmacol. 338: 225–32. doi:10.1016/s0014-2999(97)81925-5. PMID 9424016.
  7. ^ Jones, G; Dejesus-Rosario, N; Kao, C; Larsen, L; Chiavacci, R; Pallotto, A; Kurian, C (2015). Exploratory Dose-Escalation Study of NFC-1 in ADHD Adolescents With Glutamatergic Gene Network Variants. American Academy of Child and Adolescent Psychiatry.
  8. ^ ClinicalTrials.gov. "Efficacy and Safety of NFC-1 in Adolescents With Genetic Disorders Impacting mGluR and ADHD".
  9. ^ Sharma, B. "Medgenics: NFC-1 Could Be A Key Future Revenue Driver".
  10. ^ "Medgenics Announces Enrollment of First Patient in Phase 2/3 Clinical Trial of NFC-1 in Adolescents With mGluR Mutation Positive ADHD". MarketWired.


Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=Fasoracetam&oldid=783566166"